In January, as the tides of the Pacific signal new directions for the global biopharmaceutical industry, the 44th J.P. Morgan Healthcare Conference successfully concluded on January 15, 2026, in San Francisco.

As one of the largest healthcare investment and industry collaboration events worldwide, this “industry barometer” gathered over 8,000 participants, including global industry leaders, more than 500 listed companies, thousands of startups, and technology innovators to explore emerging trends and partnership opportunities.

Dr. Yi Yueneng, Chairman of Hunan YINENG Biopharmaceutical Co., Ltd. (hereinafter “YINENG Pharma”) and recipient of the China Pharmaceutical Development Award for Outstanding Achievement in Innovative Drugs, was invited to attend. He presented China’s approach to the modernization of traditional Chinese medicine (TCM), becoming a distinctive highlight of “Eastern innovation” at the conference.

AI + CXO Platform Driving TCM Innovation

As a leading Chinese TCM CXO (Contract Research, Development, and Manufacturing Organization) enterprise, YINENG Pharma represents a vivid example of “China’s iteration speed.”

In his presentation, Dr. Yi focused on the theme of the “AI + CXO TCM Innovation Technology Platform,” explaining how the company has built a full-industry-chain competitive advantage in TCM R&D:

• A 50,000 m² integrated R&D laboratory and intelligent pilot-scale research base, enabling seamless processes from raw herbal research to formulation manufacturing
• A multidisciplinary research team of nearly 400 experts led by academicians
• A comprehensive TCM database covering 592 single herbs and over 1.6 million batches of research data

Together, these capabilities form a closed-loop system of data-driven R&D and AI-enabled industrialization.

Case Study: Linggui Zhugan Granules Development

Dr. Yi highlighted the development of the approved classical formula Linggui Zhugan Decoction granules as a key example:

• AI algorithms were used to accurately define standards for geo-authentic medicinal materials
• Machine learning optimized extraction processes, significantly shortening the development cycle
• Clinical efficacy data supported predictive modeling, improving formulation evaluation accuracy

To date, YINENG Pharma has:

• Completed standardized research on 97 classical TCM formulas
• Advanced 26 innovative TCM drug development projects
• Provided technical support to over 100 pharmaceutical companies and 200 hospitals
• Helped clients obtain 67 drug approvals

These tangible achievements impressed many international participants, who noted that TCM innovation can also achieve remarkable “technological acceleration.”

Global Attention on AI + CXO Model

During networking sessions at the conference, the pace of global innovation was seen to be increasingly influenced by East Asia—especially China’s R&D efficiency.

YINENG Pharma’s “AI + CXO” model became a focal point for multinational pharmaceutical companies and investment institutions. In response to growing global interest, Dr. Yi outlined a clear internationalization strategy:

• Establish regional service centers in Europe and North America within the next three years
• Expand the AI + CXO model to global partners
• Promote integration between TCM and the global healthcare system

This appearance marked the first global capital market showcase of AI-powered TCM innovation technologies.

Strong R&D Infrastructure Supporting Global Expansion

YINENG Pharma’s global ambitions are backed by robust domestic R&D capabilities. The company has established an integrated innovation and industrial platform consisting of:

• Five major research institutes
• Six clinical application centers
• Seven core technology platforms

Equipped according to GMP standards, the facilities include pilot-scale extraction systems, spray dryers, and one-step granulation equipment, ensuring seamless integration between R&D and manufacturing.

This advanced digital TCM research center—one of the largest in China—serves as both the core engine of the AI + CXO platform and a technological landmark for TCM innovation.

From Chinese Characteristics to Global Consensus

“The modernization of traditional Chinese medicine requires both deep local roots and a global perspective,” Dr. Yi concluded in his speech.

YINENG Pharma’s participation in the J.P. Morgan Healthcare Conference represents more than a corporate milestone:

• It marks the first systematic presentation of digitalized TCM innovation by a Chinese TCM CXO company at a top-tier global healthcare event
• It signals the transition of TCM innovation from “Chinese characteristics” to “global consensus”

With the continued expansion of the AI + CXO model, TCM is evolving from an emerging force into a key pillar of the global biopharmaceutical industry.

YINENG Pharma, driven by professional R&D and digital empowerment, is positioning itself at the forefront of this transformation—charting a new future for TCM in the global healthcare landscape.

Media Contact
Company Name: Hunan Yineng Biopharmaceuticals Co., Ltd.
Email: Send Email
Country: China
Website: https://www.medgencetec.com/